Track topics on Twitter Track topics that are important to you
Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML).
Original Article: Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)NEXT ARTICLE
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...